LYON, France , April 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its next generation HIFU device: the Focal One ® .
LYON, France, Dec 18, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that it has filed a 510(k) marketing application with the U.S. Food and Drug Administration (FDA) for its newly designed, high-end Sonolith I-Sys
LYON, France, Aug 19, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that it has filed its 510(k) application for marketing clearance with the U.S. Food and Drug Administration (FDA) for its new compact and stand
LYON, France , Feb. 1, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company's Ablatherm-HIFU (
LYON, France, Sep 10, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the expansion of Ablatherm-HIFU into new territories as part of the Company's global growth strategy: * The Taiwan Department of Health
September 29, 2022 @ 8 AM ET Langham Hotel, NYC LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022
